Products
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Generics Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

ANI Brings In Record Revenues As Cortrophin Rollout Ploughs Ahead
ANI Pharmaceuticals has recorded its highest-ever quarterly revenue of $73.9m during Q2, following the launch of its cortrophin gel and a substantial growth in generics revenue.

Entry Deadline Looms For GGB Awards
There is now just one week to go until the 19 August deadline for companies to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.

UK Alendronate Prices Explode In July
An average price rise of over 1,400% was seen for alendronate 70mg tablets in the UK last month, as average prices for a host of other generics more than doubled.
Biosimilars Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Viatris Swats Away Concerns Over Divestment Valuations
Viatris remains committed to completing the sale of its global biosimilars unit to Biocon Biologics, while continuing efforts to generate up to $9bn in pre-tax proceeds by the end of 2023 from divestments.

Entry Deadline Looms For GGB Awards
There is now just one week to go until the 19 August deadline for companies to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.

Study Offers Support For Biosimilar-To-Biosimilar Switching
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.
Value-Added Medicines Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Entry Deadline Looms For GGB Awards
There is now just one week to go until the 19 August deadline for companies to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.

What’s Next? Five Things To Look Out For In August
A busy August brings patent expiries, biosimilar target action dates and the potential for a major change to biosimilar prescribing guidelines in Germany.

One Month Remains To Enter GGB Awards
Just one month remains until the 19 August deadline for companies to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.